Table 1 Clinical features and data on therapy strategy for the whole cohort
Feature | Value | Missing data | % |
|---|---|---|---|
Gender | |||
Female | 67 | - | 70 |
Male | 28 | - | 30 |
Age (year) | |||
< 4 | 43 | - | 45 |
4–10 | 25 | - | 26 |
> 10 | 27 | - | 28 |
Clinical presentation a | |||
Virilization | 55 | 9 | 64 |
Cushing syndrome | 22 | 11 | 26 |
Hypertension | 19 | 11 | 23 |
Palpation of a mass | 11 | 11 | 13 |
No clinical symptom | 3 | 11 | 4 |
Functional tumor | 74 | 11 | 88 |
Tumor diameter (by imaging) | |||
2–5 cm | 40 | 43 | |
5–10 cm | 36 | 39 | |
> 10 cm | 16 | 17 | |
Data not specified | 3 | ||
Stage (Children’s Oncology Group staging) | |||
I | 54 | 58 | |
II | 16 | 17 | |
III | 18 | 19 | |
IV | 5 | 5 | |
Data not specified | 2 | ||
Initial percutaneous biopsy | 9 | 6 | 10 |
Initial surgery | 86 | 90 | |
Results of initial surgery | |||
No residual tumour | 71 | 83 | |
Micro- or macroscopic residual tumour (including tumor rupture) | 14 | 16 | |
Data not specified | 1 | ||
No initial surgery | 7 | 7 | |
Biopsy only | 2 | 2 | |
Delayed surgery (after pre-operative therapy) | 5 | 5 | |
Data non-specified on surgery modalities | 2 | ||
Medical therapies | |||
Mitotane | 20 | 22 | |
Neoadjuvant | 4 | ||
Adjuvant | 13 | ||
Both | 3 | ||
Data not specified | 5 | ||
Conventional chemotherapy regimens | 13 | 15 | |
Neoadjuvant | 4 | ||
Adjuvant | 8 | ||
Both | 1 | ||
Data not specified | 6 | ||
Radiation therapy | 1 | 8 | 1 |
Initial | 0 | ||
Palliative | 1 | ||
